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Basophil Phenotypes in Chronic Idiopathic Urticaria
in Relation to Disease Activity and Autoantibodies
John A. Eckman1, Robert G. Hamilton1, Laura M. Gober1, Patricia M. Sterba1 and Sarbjit S. Saini1
Potentially pathogenic IgG autoantibodies to IgE or its receptor, FceRIa, have been detected inB40% of chronic
idiopathic urticaria (CIU) patients. CIU patients’ basophils display distinct altered FceRIa-mediated degranula-
tion. CIU patients with basophil histamine release in response to polyclonal goat anti-human IgE X10% are
classified as CIU responders (CIU-R) ando10% are CIU non-responders (CIU-NR). We compared the presence
of autoantibodies to basophil degranulation phenotypes and to disease status (active or inactive). Sera were
collected from non-CIU subjects and CIU subjects who participated in a longitudinal study of disease severity
and had defined basophil degranulation phenotypes. Immunoenzymetric assays (IEMA) quantified IgG anti-
FceRIa and anti-IgE. IgG anti-FceRIa antibody was detected in 57% of CIU-R (n¼ 35), 55% of CIU-NR (n¼ 29), and
57% of non-CIU subjects (n¼ 23), whereas IgG anti-IgE was present in 43% of CIU-R, 45% of CIU-NR, and 30% of
non-CIU subjects. Both the autoantibody levels and the functional basophil phenotype remained stable in
subjects with active disease (n¼ 16), whereas there was an enhancement in basophil function as subjects
evolved into a state of remission (n¼ 6), which appears independent of the presence of autoantibody. IEMAs
detected a similar frequency of autoantibodies in CIU-R, CIU-NR, and non-CIU subjects. Basophil function may
be independent of IEMA-detected autoantibodies.
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INTRODUCTION
Chronic idiopathic urticaria (CIU) is a clinical state that is
defined by 46 weeks of hives with no identifiable cause
(Greaves, 1995). Its prevalence is approximately 0.1% in the
United States (Greaves, 2000). CIU has the greatest impact on
the quality of life of any allergic disease (O’Donnell et al.,
1997; Grob and Gaudy-Marqueste, 2006) and this impact is
similar to that of coronary heart disease and severe atopic
dermatitis (O’Donnell et al., 1997; Poon et al., 1999). The
economic burden is comparable to that of other skin
conditions such as bullous skin diseases and vitiligo, which
require multiple medications, medical evaluations, work
absences, and emergency department use (Bickers et al.,
2006; Delong et al., 2008).
Although the pathogenesis of the majority of cases is
unknown, an autoimmune process has been proposed for a
subset of CIU subjects (Kaplan, 2004). Approximately
35–40% of patients with CIU are thought to possess IgG
autoantibodies to the a-subunit of the high-affinity IgE
receptor (FceRIa) (Hide et al., 1993; Fiebiger et al., 1995;
Zweiman et al., 1996; Tong et al., 1997) and approximately
5–10% have naturally occurring IgG anti-IgE autoantibodies
(Gruber et al., 1988; Grattan et al., 1991). These auto-
antibodies are thought to participate in the pathogenesis by
directly activating skin mast cells in a complement-depen-
dent manner to generate urticaria.
Functional IgG autoantibodies have been demonstrated
in vitro using the histamine release activity (HRA) assay
(Hide et al., 1993; Fiebiger et al., 1995, 1998; Kikuchi and
Kaplan, 2001; Soundararajan et al., 2005). The histamine-
releasing activity factor has been localized to the IgG fraction
of serum of CIU patients (Hide et al., 1993; Zweiman et al.,
1996; Fiebiger et al., 1998; Kikuchi and Kaplan, 2001), and
the specificity for the FceRIa has been demonstrated in a
limited number of samples (Hide et al., 1993; Kikuchi and
Kaplan, 2001). ELISA and western blot analyses have been
developed to measure IgG anti-FceRIa, and the concordance
with HRA has been poor (Fiebiger et al., 1998; Kikuchi and
Kaplan, 2001; Soundararajan et al., 2005). Thus, defining the
presence of autoantibodies in CIU serum is complicated by
the lack of a ‘‘gold standard’’ test that confirms the diagnosis
of autoimmune urticaria (Sabroe and Greaves, 2006).
Another line of investigation has shown that blood
basophils from CIU subjects have altered IgE receptor-
mediated degranulation (Greaves et al., 1974; Kern and
Lichtenstein, 1976; Sabroe et al., 1998; Luquin et al., 2005;
Vonakis et al., 2007) Recently, we reported that the ex vivo
activation of basophils from CIU subjects with an optimal
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dose of polyclonal anti-IgE antibodies segregates them into
two groups on the basis of degree of their histamine release:
responders (CIU-R) and non-responders (CIU-NR) (Vonakis
et al., 2007). CIU subjects with non-responder basophils
showed depressed histamine release, whereas basophils of
CIU subjects with a responder phenotype displayed hista-
mine release similar to that of healthy control subjects
(Vonakis et al., 2007). Basophil functional phenotype is
stable on or off medication (Vonakis et al., 2007). Demo-
graphics of the groups have been published elsewhere
(Baker et al., in press).
Given the existence of basophil functional phenotypes, we
examined the relationship of autoantibody presence and the
basophil functional phenotype in CIU subjects with active
and remissive CIU disease. In this study, we used a panel of
analytically sensitive immunoenzymetric assays (IEMA) to
measure IgG anti-FceRIa and naturally occurring IgG anti-IgE
autoantibodies in the serum of CIU subjects over time and in
relation to their basophil phenotype (CIU-R and CIU-NR).
RESULTS
IgG anti-FceRIa in the sera from CIU and non-CIU subjects
Sera collected from CIU subjects as part of basophil
phenotyping studies (n¼73) were analyzed for the level of
IgG anti-FceRIa autoantibodies. Of these subjects, 64 had
sufficient basophils present in their venous blood sample to
allow characterization of their basophil histamine release
profile as CIU-R (n¼35) or CIU-NR (n¼29). The remaining
nine subjects were basopenic and labeled ‘‘CIU-unclassi-
fied’’. Using the minimal detectable limit of 200 ngml1,
57% of CIU-R subjects (n¼ 35) and 55% of CIU-NR subjects
(n¼29) had positive IgG anti-FceRIa antibody levels (two-
tailed Fisher’s exact test, P¼1.00), whereas 67% of
CIU-unclassified subjects (n¼ 9) had detectable antibody
(two-tailed Fisher’s exact test CIU-RþCIU-NR versus CIU-
unclassified subjects, P¼0.72) (Figure 1a). The latter result
was shown to compare the presence of autoantibodies in the
sera of CIU subjects with measurable basophil histamine
content with that of CIU subjects with extremely low basophil
histamine content. The average IgG anti-FceRIa anti-
body titers were significantly higher for the CIU-unclassified
subjects (CIU-R: 330±58 ngml1 (SEM), CIU-NR: 322±
50 ngml1, and CIU-unclassified: 815±262ngml1; two-
tailed t-test CIU-RþNR versus CIU-unclassified, Po0.001).
For non-CIU subjects, 57% (n¼ 23) had detectable IgG
anti-FceRIa in their serum, which was not significantly
different from CIU subjects (59%, n¼73) (two-tailed Fisher’s
exact test, P¼1.00). The mean concentration of IgG anti-
FceRIa in CIU subjects versus non-CIU subjects was also
not significantly different (CIU: 389 ngml1, non-CIU:
304 ngml1; two-tailed t-test, P¼ 0.38).
IgG anti-IgE presence in the sera from CIU and non-CIU
subjects
The same sera were also analyzed for IgG anti-IgE antibodies.
Forty-three percent of CIU-R subjects (n¼35) and 45% of
CIU-NR subjects (n¼29) had detectable levels (two-tailed
Fisher’s exact test, P¼ 1.00), whereas 67% of unclassified
subjects without a clear basophil functional category (n¼ 9)
had detectable levels (two-tailed Fisher’s exact test CIU-
RþCIU-NR versus CIU-unclassified, P¼ 0.29) (Figure 1b).
The average IgG anti-IgE antibody titers were significantly
higher for CIU-unclassified subjects (CIU-R: 267±63 ngml1
(SEM), CIU-NR: 197±22 ngml1, and CIU-unclassified:
950±436ngml1; two-tailed t-test CIU-R/NR versus
CIU-unclassified, Po0.01).
For non-CIU subjects, 30% (n¼ 23) had detectable IgG
anti-IgE in their serum, which was not significantly different
from CIU subjects (n¼ 73) (two-tailed Fisher’s exact test,
P¼0.24). The mean IgG anti-IgE concentration in CIU
versus non-CIU subjects was not significantly different (CIU:
322 ngml1, non-CIU: 339 ngml1; two-tailed t-test,
Po0.91).
The distributions of both antibodies in CIU and non-CIU
subjects are shown in Tables 1 and 2. Notably, no correlation
was seen between the degree of basophil IgE receptor-
stimulated response and the IgG anti-FceRIa or IgG anti-IgE
titers (data not shown).
Specificity of the IgG anti-FceRIa IEMA
Specificity of the anti-FceRIa autoantibody assay was
confirmed with a dose-dependent competitive inhibition
using an overnight incubation of soluble FceRIa with six sera
containing the highest levels of IgG anti-FceRIa detected in
the study (Figure 2). The serum of each subject contained
4400ngml1 of IgG anti-FceRIa antibody and was shown to
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Figure 1. Autoantibody levels in CIU and non-CIU subjects. (a) IgG
anti-FceRIa levels in CIU subjects and non-CIU subjects. (b) IgG anti-IgE
levels in CIU and non-CIU subjects. CIU subjects are categorized based on
basophil phenotype.
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contain FceRIa-specific IgG antibody by demonstrating
inhibition with 2,400 ngml1 soluble FceRIa. The mean
inhibition for 39 subjects’ sera was 79% (SEM¼ 2%), with a
maximum inhibition of 97% (data not shown).
Correlation of basophil functional phenotype and
IEMA-measured IgG anti-FceRIa and IgG anti-IgE antibody
levels in subjects with persistent CIU disease
Of the 64 CIU subjects with defined basophil phenotype,
basophil functional profiles were measured repeatedly over
time in 25 CIU subjects (CIU-R: n¼ 12 and CIU-NR: n¼13)
with active disease (Figure 3a). In 12 subjects who were
initially CIU-R, 31 of 33 (94%) subsequent basophil
functional profile measurements repeated over time during
active disease remained within the CIU-R group. In 13
subjects who were initially CIU-NR, 20 of 21 (95%)
subsequent basophil functional profile measurements
repeated over time during active disease remained in the
CIU-NR category. The time between visits is listed in Table 3.
IgG anti-FceRIa (Figure 3b) and IgG anti-IgE (Figure 3c)
levels were determined over time in serum samples from 16
(CIU-R: n¼7 and CIU-NR: n¼9) of the 25 CIU subjects with
active disease and established basophil functional profiles
described above. In 16 subjects with persistent disease, 20 of
23 (87%) repeated measurements showed no change in their
IgG anti-FceRIa antibody status, whereas 22 of 23 (96%) IgG
anti-IgE antibody levels did not change statistically over time.
Interestingly, the subject with the greatest change, a twofold
increase in IgG anti-FceRIa antibody level, had no detectable
Table 2. Frequency of IgG autoantibodies in non-CIU
subjects (n=23)
IgG anti-IgE-positive
13 (57%)
IgG anti-IgE-negative
10 (43%)
IgG anti-FceRIa-positive
7 (30%)
6 (26%) 1 (4%)
IgG anti-FceRIa-negative
16 (70%)
7 (30%) 9 (39%)
CIU, chronic idiopathic urticaria.
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Figure 2. Dose-dependent inhibition of detectable IgG anti-FceRIa
antibodies of six CIU subjects’ sera with increasing concentrations of soluble
FceRIa.
Table 1. Frequency of IgG autoantibodies in CIU
(n=73)
IgG anti-IgE-positive
33 (45%)
IgG anti-IgE-negative
40 (55%)
IgG anti-FceRIa-positive
43 (59%)
23 (32%) 20 (27%)
IgG anti-FceRIa-negative
30 (41%)
10 (14%) 20 (27%)
CIU, chronic idiopathic urticaria.
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Figure 3. Basophil phenotypes and autoantibody levels during active
disease. (a) Basophil histamine release to 0.1 mgml1 anti-IgE over time in
CIU subjects with active disease (CIU-R (red circles): n¼12; CIU-NR
(blue triangles): n¼ 13). (b and c) IgG anti-FceRIa levels (b) and IgG
anti-IgE levels (c) over time in CIU subjects with active disease
(CIU-R (red): n¼7; CIU-NR (blue): n¼ 9).
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change in CIU severity as measured by a standardized
disease status questionnaire (Baker et al., in press).
Correlation of basophil functional phenotype and IgG
anti-FceRIa and IgG anti-IgE autoantibodies in subjects
experiencing disease remission
During the study period, six CIU subjects (CIU-R: n¼ 1 and
CIU-NR: n¼5) entered disease remission, defined by no hive
symptoms or medication use for 2 months. In disease
remission, the CIU-R donors’ basophils demonstrated heigh-
tened sensitivity to 0.01 mgml1 anti-IgE. Interestingly, the
basophils of the five CIU-NR subjects who experienced
disease remission demonstrated an increase in the magnitude
of maximal histamine release in response to the optimal
concentration of anti-IgE (0.1 mgml1) (two-tailed t-test,
P¼0.03) (Figure 4a). In contrast to these dramatic shifts in
basophil IgE receptor function, IEMA-measured IgG anti-
FceRIa (Figure 4b) and IgG anti-IgE (Figure 4c) antibody levels
did not exhibit any significant change in CIU subjects with
disease remission. The range of time between active disease
and disease remission was 6–54 months (mean¼ 20 months).
DISCUSSION
In this study, we demonstrate that the prevalence and
quantitative levels of IgG anti-FceRIa and anti-IgE in CIU
subjects were similar to those measured in the serum of the
non-CIU population. The specificity of the FceRIa-specific
autoantibody IEMA was also confirmed with B80% soluble
FceRIa-specific inhibition for all antibody-positive samples
above 400 ngml1. Moreover, our data indicate that the
pattern of basophil functional phenotypes among CIU
patients (CIU-R and CIU-NR) appears to be independent of
both the presence and the relative levels of these auto-
antibodies. Among CIU subjects, both the basophil functional
phenotypes and the IgG anti-FceRIa and anti-IgE autoanti-
body levels remain stable in subjects with persistent disease.
Importantly, however, we noted a remarkable enhancement
in basophil function as subjects evolved into a state of
remission, which appears to be independent of the presence
of an autoantibody.
The observed shift in patterns of basophil histamine
release with remission suggests that abnormal basophil
function may be a primary feature of the pathogenesis
associated with urticaria. These shifts observed in our study
are consistent with the observation of Kern and Lichtenstein
(1976), who also reported a dramatic increase in basophil
responsiveness to anti-IgE in CIU patients who experienced
remission. Although the level of autoantibodies was the
highest in select subjects with extreme basopenia, the
measures of disease severity were not clearly elevated in
these subjects. These findings may point to a primary
abnormality in the basophil and/or unknown serological
factors affecting basophils in CIU patients as more relevant to
urticarial disease pathogenesis than the presence or level of
either FceRIa- or IgE-reactive autoantibodies as measured by
IEMA.
Historically, IgG anti-FceRIa and IgG anti-IgE antibodies
have been measured by ELISA or western blot analysis and
then compared with mediator release results from the HRA
assay. Although the HRA assay, in theory, can detect
‘‘functional’’ autoantibodies that crosslink the IgE–FceRIa
receptor complex, it depends on the unique characteristics of
Table 3. Time between visits in CIU subjects with active disease
Visits 1–2 2–3 3–4 4–5 5–6 6–7
CIU-R range in months (mean) 0.5–41.5 (10.5) 1–59 (12.2) 2–18.3 (7.6) 2–6 (3.2) 3.8–13 (8.4) 7.8 (7.8)
CIU-NR range in months (mean) 1–23.8 (8.1) 0.5–6 (2.5) 2.6–8 (4.5) 1.75–2.1 (1.9) — —
CIU, chronic idiopathic urticaria; CIU-R, CIU responders; CIU-NR, CIU non-responders.
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Figure 4. Basophil phenotypes and autoantibody levels in disease remission.
(a) Basophil histamine release in CIU subjects (CIU-R: n¼ 1, to 0.01 mgml1
anti-IgE; CIU-NR: n¼ 5, to 0.1mgml1) with active disease who enter disease
remission. (b and c) IgG anti-FceRIa levels (b) and IgG anti-IgE levels (c) over
time in CIU subjects who enter disease remission.
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the normal basophils that have been selected to perform the
assay (Grattan et al., 1991; Hide et al., 1993; Zweiman et al.,
1996; Kikuchi and Kaplan, 2001). In addition, this test has
been limited by the behavior of the basophils from the
various donors (MacGlashan, 1994; Zweiman et al., 1996)
and a general lack of universal standardized reagents to
permit reproducible and verifiable comparisons across
laboratories. Our empirical data indicate extensive variability
in the HRA assay (data not shown); therefore, we elected not
to use the HRA assay in the present analysis. Previous studies
have reported a poor correlation between the presence or
relative levels of IgG anti-FceRIa, as measured by western
blot or ELISA, and the magnitude of histamine, as detected in
the HRA assay (Fiebiger et al., 1998; Kikuchi and Kaplan,
2001; Soundararajan et al., 2005). We acknowledge that
‘‘non-functional’’ autoantibodies may exist. However, the
western blot approach used in the largest study to date
(Kikuchi and Kaplan, 2001) may not have been sufficiently
sensitive to detect the lower concentrations of functional
antibodies in the sera of CIU subjects. In the western blot
study, the serum was diluted 1:500, in contrast to the 1:100
dilution required for the ELISAs of autoantibodies. This
higher-than-desired serum dilution may have prevented the
detection of potentially non-functional antibodies with low
avidity in non-CIU subjects. In addition, western blot
measurements of IgG anti-IgE were not performed in these
studies, which could explain some of the discrepancies that
exist between previous analyses and our present results.
Previous ELISAs reportedly detected autoantibodies regard-
less of the HRA result (Soundararajan et al., 2005). In another
study, an ELISA was unable to detect ‘‘functional’’ auto-
antibodies in some subjects with a positive HRA (Fiebiger
et al., 1998). Neither study measured potentially functional,
naturally occurring IgG anti-IgE antibodies that we were able
to detect at similar frequencies in CIU and non-CIU
populations. Although our IEMA does not differentiate
between ‘‘functional’’ and ‘‘non-functional’’ antibodies, we
maximized the analytical sensitivity of our assays for both IgG
anti-FceRIa and IgG anti-IgE autoantibodies. However, we
have provided the IgE receptor function of blood basophils
obtained simultaneously with the serum sample analyzed for
autoantibodies to detect evidence of functional autoantibo-
dies on a cell commonly used in the HRA.
Given the importance of precision and accuracy in
diagnostic tests, the ability to run many samples in a single
assay (in contrast to western blot analysis), and the inherent
problems with HRA, we decided to focus in this study on an
IEMA for the measurement of IgG anti-FceRIa and IgG anti-
IgE in serum. The design of our IgG anti-FceRIa assay is
similar to the assay used by Fiebiger et al. (1998), with several
important differences. First, we used a heterologous calibra-
tion curve that employed a humanized IgG anti-IgE antibody
(omalizumab) to estimate the amount of autoantibody in each
serum. This strategy contrasted with the use of the assay
response (optical density) by others (Fiebiger et al., 1998),
which is not always directly proportional to concentration.
Second, we defined a ‘‘positive’’ autoantibody presence on
the basis of the assay’s analytical sensitivity rather than a
response level detected in non-CIU subjects. Using a different
strategy for defining autoantibody-positive CIU subjects, we
detected a higher prevalence of FceRIa-reactive autoanti-
bodies in normal subjects. Moreover, using Fiebiger’s
‘‘positive’’ criteria as the mean in non-CIU subjects plus 2.5
times the SEM, IgG anti-FceRIa would still have remained
positive in 26% of our CIU subjects and 22% of our non-CIU
subjects. Using these same criteria, IgG anti-IgE would have
been positive in 7% of CIU subjects and 4% of non-CIU
subjects. Thus, using either strategy for defining autoanti-
body-positive subjects, both CIU and non-CIU groups had
similar frequencies of autoantibody positivity. An explanation
for the detection of autoantibodies in non-CIU subjects in our
study, in contrast to previously reported studies, may be a
consequence of our assay’s heightened analytical sensitivity
and our method of establishing the detection threshold based
on each assay’s actual analytical sensitivity rather than simply
using the levels of binding detected with sera from a non-CIU
population. However, other groups have reported naturally
occurring anti-IgE and anti-FceRIa in non-CIU subjects
(Quinti et al., 1986; Fiebiger et al., 1998; Horn et al.,
1999). In addition, the autologous serum skin test, considered
to reflect the presence of functional anti-IgE and anti-FceRIa,
was positive in 35% of non-CIU subjects in one study
(Guttman-Yassky et al., 2007).
The limitations of our IEMA include the lack of a true
autoantibody standard for determining the precise amount of
antibody present. Nevertheless, a heterologous calibration
curve has been successfully used to calibrate other antibody
assays (Butler, 1991). Second, we did not measure the
subclass distribution of the IgG antibodies. It was originally
suggested by Fiebiger et al. (1998) that complement-activa-
ting IgG1 and IgG3 are present more frequently in CIU
subjects than in non-CIU subjects. This observation was later
supported by the lack of IgG2 antibodies in the sera of CIU
subjects but evidence for IgG4 autoantibodies in sera from
CIU subjects (Soundararajan et al., 2005). With no known
subclass-specific standard for the antibodies of interest and
different binding constants for the different subclass detection
antibodies, the accurate detection of these subclasses remains
challenging (Hamilton, 1987). Finally, because our assay
does not differentiate potentially functional from non-func-
tional autoantibodies, it is possible that there are still
differences in the amount of functional antibodies between
CIU and non-CIU subjects.
In summary, these studies support the conclusion that
altered basophil IgE receptor function is a reproducible
finding in active CIU that appears to reflect disease remission.
This basophil functional abnormality appears to be indepen-
dent of autoantibody presence as measured by IEMA and
suggests unknown serological factors or primary basophil
abnormalities in the pathogenesis of CIU.
MATERIALS AND METHODS
Reagents
Pharmaceutical grade omalizumab was purchased from Genentech
(South San Francisco, CA) and reconstituted as recommended in the
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package insert. The 147mgml1 stock was further diluted
with phosphate-buffered saline containing 1% BSA (PBS-BSA).
Omalizumab was then coupled to Sepharose at 1mgml1 after
activation with cyanogen bromide (Schellenberg and Adkinson,
1975) and washed in PBS-BSA. Human serum (diluted 1:10, 0.1ml)
was added to 5% (vol/vol) omalizumab–Sepharose in PBS-BSA and
rotated overnight at 23 1C to remove IgE for some assay analyses.
Murine IgM anti-human IgE mAb (clone HP6061; Reimer, 1986;
Hybridoma Reagent Laboratory, Baltimore, MD) was added to
microtiter plates at 10 mgml1 in PBS (pH 7.4) and used as a human
IgE capture reagent. Streptavidin (Sigma-Aldrich, St Louis, MO) was
added to microtiter plates at 20 mgml1 in PBS (pH 7.4) to capture
biotinylated human FceRIa chain. Horseradish peroxidase-conju-
gated murine monoclonal anti-human IgG Fc (clone HP6043;
Hamilton and Morrison, 1993; Hybridoma Reagent Laboratory)
was used at 1mgml1 as the human IgG detection protein.
A recombinant truncated form of the extracellular domain (amino
acids 1–172) of the a-chain of the high-affinity human IgE receptor
(FceRIa; Heska Corporation, Fort Collins, CO) was produced in a
baculovirus expression system and biotinylated as described
previously (Stedman et al., 2001).
Polyclonal IgE (JK, Baltimore, MD; diluted to 2 mgml1 in
PBS-BSA) was used as a source of human IgE.
Human specimens
After consent was obtained, whole blood for basophil and serology
studies was collected from subjects with a physician-determined
diagnosis of CIU (n¼ 73) as part of a longitudinal study (Gober et al.,
2006; Baker et al., in press) or from non-CIU, healthy control
subjects (n¼ 23; 10 atopic and 13 non-atopic from history) using
protocols approved by the Johns Hopkins Institutional Review Board
(IRB) and the Western IRB and in adherence to the Declaration of
Helsinki Principles.
Basophil isolation and histamine release
Basophil studies were performed as described previously (Vonakis
et al., 2007). Briefly, venous blood was drawn into a syringe
containing 5–10mM EDTA. Mixed leukocytes were obtained using
dextran sedimentation with average basophil purity o1%. These
cells were stimulated for histamine release with polyclonal goat anti-
human IgE (0.01–3 mgml1) or N-formyl-met-leu-phe (FMLP;
1mmol l1) for 45minutes at 37 1C. Histamine was quantified in
cell-free supernatant using an automated fluorometric assay
(Siraganian, 1975). Results were computed as the percentage of
total histamine release in a total cell lysate of leukocyte aliquots
after subtraction of the spontaneous histamine release.
CIU subjects were grouped on the basis of their ability to release
histamine after incubation of basophils with an optimal dose of anti-
IgE (0.1 mgml1) as described previously (Vonakis et al., 2007).
Subjects with histamine release o10% were classified as CIU-NR,
whereas subjects with histamine release X10% were classified as
CIU-R. Subjects with total (complete) histamine release o5 ngml1
were designated CIU-unclassified.
Human IgG anti-FceRIa IEMA
Plate preparation. Streptavidin diluted in PBS was adsorbed
(0.1ml per well) onto the bottom six rows of a sterile flat-bottom
polystyrene 96-well Bacti plate (Nalge-Nunc International,
Rochester, NY). Concurrent with the streptavidin-coating step, a
murine IgM anti-human IgE Fc (clone HP6061P diluted in PBS;
0.1ml per well) was adsorbed onto the top two rows of each plate to
establish a calibration curve. The plates were incubated 16–18 hours
at 2–8 1C. This was followed by a buffer wash (PBS containing 0.05%
Tween 20 and 0.01% thimerosal (PBS-Tween)). Unreacted sites were
then blocked with PBS-BSA (0.3ml per well) for 1 hour at 231C.
Unknown and calibration serum preparation. IgE-depleted test
sera (diluted to 1:100 in PBS-BSA) were incubated for 3 hours at
37 1C with biotinylated FceRIa (final concentration 60 ngml1) or
PBS-BSA (sham control). For the calibration portion of the assay, 11
twofold dilutions of omalizumab were prepared with human IgG
anti-IgE Fc concentrations from 1ngml1 to 1 mgml1.
Antibody binding and detection. The blocked plate was washed
five times with PBS-Tween and all wells in the top two calibration
rows with bound mouse anti-human IgE Fc received polyclonal
human IgE (2 mgml1 final IgE concentration, 0.1ml per well). The
bottom wells containing streptavidin received 0.1ml PBS-BSA. After
1 h incubation, the whole plate was washed with PBS-Tween and the
IgE-depleted sera of test subjects (0.1ml per well, with or without
biotin–FceRIa) were added to their respective wells in the bottom of
the plate coated with streptavidin. The omalizumab (1 ngml1 to
1mgml1) was pipetted into replicate wells in the top calibration
portion of the plate. The entire plate was incubated for 1 h at 231C.
Detection of bound human IgG. The entire plate was washed
five times with PBS-Tween and peroxidase-conjugated mouse anti-
human IgG (HP6043-HRP, 1mgml1, 0.1ml per well) was added
to all wells. The plate was incubated for 1 h at 23 1C and then
washed five times in PBS-Tween. 2,20-azino-bis (3-ethylbenzthiazoline-
6-sulfonic acid) (ABTS) substrate (0.1ml per well), containing 1ml of
H2O2 per milliliter of ABTS, was pipetted into each well. After
60–75minutes, the plate was read in an ELISA plate reader (MR4000;
Dynatech Technologies, McLean, VA) at 405 nm. This calibration
curve constructed with omalizumab binding to insolubilized human
IgE was used to interpolate the level of IgG anti-FceRIa in the test
sera. Reproducibility was confirmed with interassay coefficients of
variation o9% (n¼ 8) of reference specimens analyzed on each
plate.
Competitive inhibition of anti-FceRIa assay
To confirm specificity, a competitive inhibition format of the IgG
anti-FceRIa antibody IEMA was performed. Unlabeled soluble
FceRIa (serial dilutions from 75ngml1 to 2.4 mgml1) was added
to IgE-depleted sera containing IgG anti-FceRIa. After an overnight
incubation at 4 1C, the specimens were analyzed in the IgG anti-
FceRIa antibody IEMA at a final concentration of 1:100 as discussed
above. Percentage inhibition of binding was computed.
Human IgG anti-IgE immunoenzymetric assay
Naturally occurring IgG anti-IgE in human sera was measured using
a solid-phase IEMA as discussed previously (Lichtenstein et al.,
1992). In brief, monoclonal murine IgM, anti-human IgE Fc in PBS
(clone HP6061P) was absorbed onto sterile flat-bottom polystyrene
96-well Bacti plates (0.1ml per well; 16–18 hours at 2–8 1C). The
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plates were washed five times with PBS-Tween and subsequently
blocked with PBS-BSA (0.3ml per well). Two hours later, the plates
were washed five times with PBS-Tween, and then polyclonal IgE
(2mgml1 final IgE concentration, 0.1ml per well) was added to
each well. After a 1-hour incubation at 23 1C, the plates were
washed five times with PBS-Tween and sera of the subjects (non-IgE
depleted) were added to the wells (0.1ml per well, 1:100 final
dilution). HP6043-HRP (1mgml1, 0.1ml per well) was then added,
and the plates were incubated for 1 h at 23 1C. After an additional
buffer wash, ABTS substrate (0.1ml per well), containing 1 ml of
H2O2 per milliliter of ABTS, was added and processed as discussed
for the IgG anti-FceRIa assay. Adsorbance at 280 nm for the
unknown specimens was interpolated from the omalizumab hetero-
logous calibration curve into estimates of IgG antibody bound as
described above. Reproducibility was demonstrated with interassay
coefficients of variation o20% (n¼ 8) of reference curve dilutions
analyzed on each plate.
Minimal detectable concentration
The minimal detectable concentration of IgG anti-FceRIa and IgG
anti-IgE antibodies was determined using a t-test to determine what
human IgG anti-IgE (omalizumab) concentration was significantly
different (495% confidence) from the buffer blank (absence of
antibody). The minimum detectable concentration was determined
to be 200 ngml1 of IgG anti-human IgE. ValuesX200 ngml1 were
considered to be significantly detectable, or ‘‘positive’’.
Statistical design
Two-tailed Fisher’s exact test was used for nonparametric analysis,
whereas two-tailed t-test was used for normally distributed data. A
P-value less than 0.05 was considered significant. All error bars
represent SEMs.
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